Ironwood Pharmaceuticals (IRWD) PT Raised to $16 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts IRWD Hot Sheet
Price: $3.62 +0.28%
Rating Summary:
11 Buy, 14 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Rating Summary:
11 Buy, 14 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Join SI Premium – FREE
JPMorgan analyst Eric Joseph raised the price target on Ironwood Pharmaceuticals (NASDAQ: IRWD) to $16.00 (from $13.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Exlservice (EXLS) PT Raised to $48 at Stifel
- Baxter International (BAX) PT Lowered to $25 at Jefferies
- Ligand Pharma (LGND) PT Raised to $350 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
